MHE Talks: Patient Access to Multiple Sclerosis Care with Thomas P. Leist of Jefferson University Hospitals

People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.

Researchers say patient-reported disability can be used as a metric in outcomes-based contracts related to the care of multiple sclerosis patients.

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative conditions

But three — tolebrutinib, fenebrutinib, and remibrutinib — are now in late-stage trials.

One of the projects involves,studying a type of cholesterol that may promote myelin repair.

Segesterone acetate is a laboratory-made derivative of progesterone, a sex hormone used in many hormonal contraceptives